Bendamustine Liquid Formulation Stability via Solvent Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bendamustine's instability in aqueous solutions necessitates lyophilization and reconstitution, which is time-consuming and costly, and existing propylene glycol formulations are not commercially viable due to degradation issues.
Innovation Solution
Development of liquid pharmaceutical formulations comprising bendamustine with a polar aprotic solvent, such as dimethylacetamide or dimethyl sulfoxide, and a non-aqueous polar protic solvent, like propylene glycol, that maintain stability over commercial storage periods without the need for lyophilization or reconstitution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If bendamustine is formulated as a lyophilized powder for injection, then stability is improved, but ease of operation deteriorates due to time-consuming reconstitution
Solution Approach 1:
The patent changes the physical state parameter from solid lyophilized powder to liquid formulation, and modifies the solvent composition parameters to achieve both stability and ease of use. The liquid formulation eliminates the need for reconstitution while maintaining stability through carefully selected solvent composition.
2Stability of the object's composition
If bendamustine is formulated as a lyophilized powder, then stability is improved, but device complexity increases due to specialized equipment requirements
Solution Approach 1:
The patent changes the formulation state from solid to liquid, eliminating the need for lyophilization equipment and specialized reconstitution devices. This parameter change simplifies the manufacturing and administration process while maintaining drug stability through appropriate solvent selection.
3Ease of operation
If aqueous solutions of bendamustine are used, then ease of operation is improved, but stability deteriorates due to hydrolysis degradation
Solution Approach 1:
The patent uses non-aqueous solvents (glycols, esters, or their mixtures) to create an inert chemical environment that prevents hydrolysis of bendamustine. These solvents provide a chemically stable medium that maintains drug integrity while allowing liquid formulation for easy administration.
Solution Approach 2:
The patent employs composite solvent systems, particularly mixtures of glycols and esters, to achieve both stability and solubility. The composite nature of these solvent mixtures provides synergistic effects that prevent degradation while maintaining drug dissolution and liquid stability.
4Ease of operation
If propylene glycol formulations are developed, then ease of operation is improved, but reliability deteriorates due to commercial viability issues
Solution Approach 1:
The patent moves from single-component propylene glycol formulations to composite solvent systems combining glycols with esters or other compatible solvents. This composite approach improves reliability by enhancing chemical stability and preventing degradation pathways that occur in pure propylene glycol, while maintaining ease of liquid administration.
Data Source
AI summary
Stable liquid formulations of bendamustine, and pharmaceutically acceptable salts thereof, and polar aprotic solvents, are described.